Identification of c-Src Tyrosine Kinase Substrates Using Mass Spectrometry and Peptide Microarrays

Ramars Amanchy,† Jun Zhong,† Henrik Molina,‡ Raghothama Chaerkady,†,‡ Akiko Iwahori,† Dario Eluan Kalume,†,⊥,§ Mads Grønborg,† Jos Joore,§ Leslie Cope,| and Akhilesh Pandey*,†

McKusick-Nathans Institute of Genetic Medicine and the Departments of Biological Chemistry, Pathology and Oncology, Johns Hopkins University, Baltimore, Maryland 21205, Institute of Bioinformatics, International Technology Park, Bangalore, 560066, India, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Center for Experimental Bioinformatics, Odense 5230, Denmark, Pepscan Systems, Edelhertweg 15, 8219 PH Lelystad, The Netherlands, and Sidney Kimmel Comprehensive Cancer Center and the Department of Biostatistics, Bloomberg School of Public Health, and Johns Hopkins University, Baltimore, Maryland 21205

Received March 17, 2008

C-Src tyrosine kinase plays a critical role in signal transduction downstream of growth factor receptors, integrins and G protein-coupled receptors. We used stable isotope labeling with amino acids in cell culture (SILAC) approach to identify additional substrates of c-Src tyrosine kinase in human embryonic kidney 293T cells. We have identified 10 known substrates and interactors of c-Src and Src family kinases along with 26 novel substrates. We have experimentally validated 4 of the novel proteins (NICE-4, RNA binding motif 10, FUSE-binding protein 1 and TRK-fused gene) as direct substrates of c-Src using in vitro kinase assays and cotransfection experiments. Significantly, using a c-Src specific inhibitor, we were also able to implicate 3 novel substrates (RNA binding motif 10, EWS1 and Bcl-2 associated transcription factor) in PDGF signaling. Finally, to identify the exact tyrosine residues that are phosphorylated by c-Src on the novel c-Src substrates, we designed custom peptide microarrays containing all possible tyrosine-containing peptides (312 unique peptides) and their mutant counterparts containing a Tyr → Phe substitution from 14 of the identified substrates. Using this platform, we identified 34 peptides that are phosphorylated by c-Src. We have demonstrated that SILAC-based quantitative proteomics approach is suitable for identification of substrates of nonreceptor tyrosine kinases and can be coupled with peptide microarrays for high-throughput identification of substrate phosphopeptides.

Keywords: Phosphorylation • SILAC • PDGF • Quantitative mass spectrometry • Systems biology

Introduction

Most signaling pathways include protein kinases and their substrates that serve as means to amplify signals from extracellular signals and other stimuli. However, the precise connectivity between protein kinases and their downstream substrates has not been fully elucidated for most protein kinases. C-Src is a classic nonreceptor tyrosine kinase that has been implicated in regulation of cytoskeletal rearrangement and cell adhesion networks that control cell migration, cell proliferation and cell survival.1 One vital step in understanding the role of C-Src kinase in cellular transformation and signaling is systematic identification of all of its potential cellular substrates involved in these processes.

Recent studies based on advances in mass spectrometry-based proteomics have provided large-scale catalogs of phosphorylation sites.2–5 However, determination of kinases responsible for these phosphorylation events is not an easy task owing to the transient interaction between kinases and their substrates. Chemical and genetic approaches have been previously used to identify C-Src substrates. Such studies include use of an ATP analogue that is a specific substrate for an analogue-specific allele of v-Src,6 screening of cDNA expression libraries with anti-phosphotyrosine antibodies7 and use of mutant inducible forms of C-Src.8 To date, several C-Src substrates as well as interactors have been reported. Human Protein Reference Database (HPRD)9 provides a list of 132 C-Src mediated phosphorylation sites in 64 known substrates along with 204 proteins that interact with C-Src.
Identification of c-Src Kinase Substrates

We have used the stable isotope labeling with amino acids in cell culture (SILAC) approach which enables identification of tyrosine kinase substrates based on a unique signature in mass spectrometry experiments.\(^{10-12}\) The main objective of this work was to identify novel c-Src substrates by overexpression of a constitutively active form of c-Src followed by enrichment of tyrosine-phosphorylated proteins. We have identified 26 novel c-Src tyrosine kinase substrates in addition to 10 others, which were either known Src family kinase substrates or proteins known to associate with Src family kinases. We have experimentally confirmed 4 novel substrates, NICE-4, RNA Binding Motif protein 10 isoform 1 (NP_05667), FUSE-binding protein 1 and TRK-fused gene, using anti-phosphotyrosine antibody (4G10) and reprobing was carried out using anti-Flag antibody.

**Experimental Procedures**

**Chemicals and Antibodies.** Stable isotope containing amino acids, \(^{12}\)C-labelled, \(^{13}\)C-labelled and \(^{15}\)N-labelled, were purchased from Cambridge Isotope Labs (Andover, MA). Complete protease inhibitor cocktail tablets were purchased from Roche (Indianapolis, IN), sodium orthovanadate and anti-Flag M2 monoclonal antibody from Sigma-Aldrich Co. (St. Louis, MO), SU6656 from EMD Biosciences, Inc. (San Diego, CA), anti-phosphotyrosine antibodies (4G10) agarose conjugate and streptavidin-agarose beads from Upstate Biotechnology (Lake Placid, NY), antiphosphotyrosine-RC20 biotin conjugate from BD Biosciences (San Jose, CA) and PDGF-BB from Invitrogen (Carlsbad, CA). Sequencing grade trypsin was purchased from Promega (Madison, WI). Antibodies against cortactin were purchased from Upstate USA, Inc. (Chicago, IL), p130CAS and EWS1 from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), BTF from Bethyl, Inc. (Montgomery, TX), and RMB10 was from Abcam, Inc. (Cambridge, MA). Phospho-Src (Tyr416) antibody and PhosphoScan Kit (P-Tyr-100) were purchased from Cell signaling technology (Boston, MA).

**Cell Culture and Stable Isotope Labeling with Amino Acid in Cell Culture (SILAC).** Human embryonic kidney 293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing ‘light’, ‘medium’ or ‘heavy’ arginine supplemented with 10% dialyzed fetal bovine serum (FBS) plus antibiotics. The 293T cells were adapted to growing in isotope rich-medium supplemented with dialyzed serum prior to initiating these experiments. In each experiment, 20 10-cm dishes were used per condition and the cells were transfected with 15 \(\mu\)g DNA using the standard calcium phosphate method (Invitrogen, Carlsbad, CA). Six hours after transfection, the cells were serum-starved for 10 or 20 h. After starvation, the cells were lysed in modified RIPA buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, and 1 mM sodium orthovanadate in the presence of protease inhibitors). Upon cell lysis, proteins lysates were either subjected to affinity purification of tyrosine phosphorylated proteins\(^{13}\) or peptides containing phosphotyrosine were enriched directly from trypsin-digested cell lysates\(^{14}\) using specific antibodies against phosphotyrosine and identified by tandem mass spectrometry.

**Immunoprecipitation and Western Blotting.** Light, medium and heavy cell lysates were precleared with protein A-agarose, mixed, and incubated with 400 \(\mu\)g of 4G10 monoclonal antibodies coupled with agarose beads, 75 \(\mu\)g of biotin-conjugated RC20 antibody, and streptavidin-agarose beads overnight at 4 \(^\circ\)C. Precipitated immune complexes were then washed three times with lysis buffer. Agarose beads were boiled and resolved by 10% SDS-PAGE. The gel was silver-stained for visualizing protein bands. Western blotting experiments were performed using anti-phosphotyrosine antibody (4G10) and reprobing was carried out using anti-Flag antibody.

**Cloning and Transfection.** NICE-4 protein (NP_055662), RNA Binding Motif protein 10 (NP_055667), Far upstream element-binding protein (NP_003893), and TRK-fused gene (NP_060061) were cloned into a Flag epitope-tagged mammalian expression vector, pCMVTag4A. 293T cells were grown in 10 cm dishes. One dish transfected with wild-type c-Src and pCMVTag4A vector as control; one was cotransfected with wild-type c-Src and Flag-tagged cDNAs. The expressed proteins were immunoprecipitated using anti-Flag antibody, followed by SDS-PAGE and Western blotting. The blots were probed with anti-phosphotyrosine antibody followed by stripping and reprobing with anti-Flag antibodies.

**In Vitro Kinase Assays Using GST-Fusion Proteins.** Fusion proteins were made using TNT-coupled rabbit reticulocyte lysate system (Promega, Madison, WI) with the cDNAs cloned in GST expression vector, PGEX4T1. The in vitro translated GST-tagged proteins were purified with 10 \(\mu\)g GST beads for 12 h at 4 \(^\circ\)C. After incubation, the beads were washed two times in lysis buffer and two times in kinase buffer (20 mM Heps, pH 7.4, 5 mM MgCl\(_2\), 2 mM MnCl\(_2\), 50 \(\mu\)M sodium vanadate, 50 \(\mu\)M DTT). Immune complexes were incubated for 30 min at 30 \(^\circ\)C in 5 \(\mu\)L of ATP mixture (10 \(\mu\)M cold ATP and 10 \(\mu\)Ci of \(^{32}\)P] ATP) and c-Src Kinase. Protein samples were then eluted by boiling in sample buffer and resolved by SDS-PAGE. The gel was dried and exposed to X-ray film to visualize the \(^{32}\)P-labeled protein bands.

**PDGF Stimulation and Inhibition of Src Kinase.** NIH3T3 cells were grown in DMEM containing 10% FBS supplemented with antibiotics. For all PDGF stimulation experiments, cells were stimulated with 100 ng/mL PDGF-BB for 5 min. For inhibition of c-Src kinase, cells were treated with 2 \(\mu\)M c-Src kinase inhibitor, SU6656, for 1 h prior to stimulation of cells with PDGF-BB for 5 min.

**In-Gel Trypsin Digestion and In-Solution Trypsin Digestion.** The silver-stained protein bands were excised and in-gel trypsin digestion was performed as described previously.\(^{15}\) Briefly, the gel slices were excised and incubated with trypsin overnight at 37 \(^\circ\)C to allow digestion of proteins after a reduction and alklylation step. After in-gel digestion, the tryptic peptides were extracted. The supernatants from the in-gel and in-solution trypsin digestion containing the peptide mixture were partially dried down in a vacufuge to approximately 10 \(\mu\)L. For in-solution digestion and enrichment of phosphopeptides, phosphoscan kit was used according to manufacturer’s prescribed conditions.

**Liquid Chromatography–Mass Spectrometry.** The extracted peptide mixture was centrifuged for 2 min at 12 000g and 4 \(^\circ\)C and resolved by reversed-phase liquid chromatography on Agilent 1100 Series LC system (Agilent Technologies, Palo Alto, CA) equipped with a well plate sampler, a vacuum degasser, and a capillary pump. Each fraction from the digested peptide mixture was analyzed by automated nanoflow LC-MS/MS. An
Agilent Technologies 1100 series system was used to deliver a flow of 1.5 µL/min during desalting of the sample and 250 nL/min during elution of the peptides into the mass spectrometer as described before. Each sample was loaded onto an online analytical fused silica needle column (Proxion Biosystems, Odense, Denmark) packed within. The washing and desalting was done with 95% mobile phase A (H2O with 0.4% acetic acid and 0.005% heptfluorobutyric (v/v)) and 5% mobile phase B (90% acetonitrile, 0.4% acetic acid, 0.005% heptfluorobutyric acid in water). Samples were eluted from the analytical column by a linear gradient of 90% mobile phase A to 60% mobile phase A. A 34-min gradient was used for elution. A potential of 2.8 kV was applied to the emitter (Proxion Biosystems). The spectra were acquired on a quadrupole time-of-flight mass spectrometer (Q-TOF US-AP, Micromass, Manchester, U.K.) equipped with an ion source sample introduction system designed by Proxeon Biosystems (Odense, Denmark). Data were obtained in positive ion mode. Data-dependent acquisition was performed with a ion mass window from 2.5 Da. MS to MS/MS switch was set to a threshold of 10 counts/s, and MS/MS to MS was set to an intensity below a threshold of 2 counts/s. Charge state recognition was used to estimate the collision energy for the fragmented precursor. Scan time was set to 0.9 s, and interscan time was set to 0.1 s. The number of components (i.e., number of MS/MS per MS scan) was set to three resulting in a total cycle time (one MS and three MS/MS spectra) of 10 s. The acquisition of data was performed using MassLynx (version 4.0). The parameters used for generating peak lists from the raw data were the following: smooth window, 4.00; number of smooth, 2; smooth mode, Savitzky Golay; and percentage of peak height to calculate centroid scores, 80% with no baseline subtraction. The generated peak lists (pkl-file) were searched against the RefSeq human protein database (build 33, 29 572 sequences) (www.ncbi.nlm.nih.gov/RefSeq/) using Mascot version 2.0, with a mass accuracy of 1.1 Da for the parent ion (MS) and 0.2 Da for the fragment ions (MS/MS), allowing a maximum of two missed cleavages. Carbamidomethylation of cysteines was considered as fixed modification, and oxidations of methionine residues, phospho-tyrosines, and amino-terminal acetylation (acetyl) were considered as variable modifications. An initial protein list was generated using the following criteria. Only proteins containing at least one unique peptide (if the sequence has not been assigned to a different protein) with a Mascot score over 30 were considered in the data set. The sequence of higher scoring peptides was manually verified. Quantitation was performed on three to four peptides (wherever available) by comparing the extracted ion chromatogram of the corresponding light and heavy peptides using MS-Quant. Reproducibility of measurements was performed by using two analysis of variance models as described earlier. The tandem mass spectra were manually verified to assign the sequence and phosphorylation sites for all peptides identified in this study (Supplementary Table 1). The phosphorylation sites were manually verified and assigned after confirmation of a mass difference of 243 Da corresponding to phosphotyrosine residue.

**Peptide Microarrays and Data Analysis.** The WT (peptides containing a tyrosine residue in the center) and MUT (peptides where the central tyrosine residue was replaced by phenylalanine) peptides (Supplementary Table 2) were each spotted as triplicates on glass slides (Pepscan Systems, Lelystad, Netherlands) as described earlier. c-Src kinase assays were carried out using these custom peptide microarrays by incubating 50 ng of recombinant c-Src Kinase (Invitrogen, Carlsbad, CA) in kinase reaction buffer and 300 µCi/ml γ32P-labeled ATP (AH9968; GE Healthcare Biosciences Corp., Piscataway, NJ) at 25 °C for 1 h in a 120 µL reaction volume supplemented with 200 µM ATP. The reaction was stopped and the following washing steps were performed: 2 washes in 2 M sodium chloride containing 1% Triton X-100 followed by 3 washes in phosphate buffered saline containing Triton X-100 and 1 wash in distilled water. The glass slides were then air-dried and exposed to the phosphorimager screen for 12 h and scanned using Biorad Molecular Image FX (Bio-Rad Laboratories, Inc., Hercules, CA). The image was processed using GenePix Pro 6.0 software (Molecular Devices Corporation, Sunnyvale, CA). Autoradiographs were obtained using a phosphorimager screen. The assay was performed in triplicate. The intensity values obtained were transformed to the log base 2 scale. Effects on intensity due to the position of the spot on the slide were estimated by performing a local regression analysis (loess) with respect to chip coordinates, and subtracted out. Normalized log 2 intensities for triplicate spots were averaged, and the mean log 2 MUT intensity was subtracted from the corresponding mean log 2 WT intensity for each peptide. The resulting background adjusted values were averaged over replicate arrays. The mean background adjusted log intensity for each peptide on the Y-axis, and the average of WT, and MUT log intensities on the X-axis were plotted to estimate the distribution of the intensity values arising from the phosphorylated peptides. A key assumption for selection of positive (phosphorylated) peptides is that WT peptide intensity values are greater than MUT peptide intensities. It is also assumed that higher intensity peptides are more likely to be positive. We note that, consistent with this assumption, the WT intensity is consistently higher than MUT intensity for the high intensity peptides on the right side of the plot. Likewise, there is greater symmetry on the left side quadrant of the MvA plot, where we expect nonphosphorylated peptides to have WT intensities that are as likely to be lower than MUT values as higher. The classical False Positive Rate (expected error rate for a set of points) is derived by evaluating symmetry in the Y-axis. For each value of A, the classical FPR blue curve gives: (number of points below the X-axis to the right of A)/(number of points above the X-axis to the right of A), and describes the expected number of false positives in the upper right quadrant of the plot. Sometimes it is desirable to estimate the probability that a single given point is a false positive, allowing us to move the threshold to the left until the price of adding one more peptide is too high. This is described by the local false positive rate curve. The local FPR curve gives the probability of a positive peptide located at A being a false positive. We selected all peptides where the local false positive rate was lower than 0.15 and WT intensities were 2-fold greater compared to MUT. The resulting set has an overall FPR of 0.085.

**Results and Discussion**

**Stable Isotope Labeling of Cellular Proteins for the Identification of c-Src Kinase Substrates.** SILAC involves metabolic labeling of cellular proteomes by growing the cells in media containing amino acids labeled with stable isotopes. SILAC enables identification of peptides labeled in vivo and relative quantitation of abundance of the peptides arising out of a mixture of labeled and unlabeled protein samples. This
Identification of c-Src Kinase Substrates

Figure 1. (A) Schematic for the integrated proteomic approach for the identification of c-Src kinase substrates. Human embryonic kidney (HEK) 293T cells growing in Arg '0' containing medium were transiently transfected with a kinase-dead Src (K298M) and 293T cells growing in Arg '6' and Arg '10' were transiently transfected with constitutively active Src kinase (Y527F). Arg '0' refers to $^{12}$C$_6$-arginine, Arg '6' refers to $^{13}$C$_6$-arginine and Arg '10' refers to $^{13}$C$_6$$^{15}$N$_4$-arginine, isotopic labeled forms of arginine used to differentially label 293T cells for identification of Src substrates.

Method also allows one to distinguish contaminating proteins in immunoprecipitates that arise due to nonspecific binding. Because of the complexity of cell lysates, and because kinase substrates generally exhibit low stoichiometry of tyrosine phosphorylation, specific identification of tyrosine kinase substrates can be facilitated by prior enrichment of tyrosine-phosphorylated proteins with anti-phosphotyrosine antibodies. We applied SILAC for the identification of the c-Src kinase substrates in human embryonic kidney cells by overexpression of a constitutively active form of c-Src followed by affinity purification of tyrosine phosphorylated proteins. We transiently overexpressed either a kinase inactive c-Src (K298M) as a control or a constitutively active c-Src (Y527F) kinase in 293T cells. Phosphorylation of the C-terminal tyrosine by C-terminal Src Kinase (CSK) allows inactivation of c-Src. Hence, mutation of this tyrosine residue to phenylalanine allows c-Src kinase to be constitutively active by preventing its folding and by allowing the kinase domain access to its substrates.

Inhibition of c-Src activity is often achieved by coexpression of the c-Src-inactivating C-terminal Src Kinase (CSK), the kinase-inactive Src mutant Src K298 M, or by treatment of the cells with c-Src inhibitors.

Three populations of human embryonic kidney cells were grown in DMEM containing $^{12}$C$_6$-arginine (light), $^{13}$C$_6$-arginine (medium) and $^{15}$C$_6$$^{15}$N$_4$-arginine (heavy), respectively (Figure 1). The cells grown in light medium were transfected with a kinase inactive c-Src as a negative control. Cells grown in medium and heavy isotope containing media were transfected with a constitutively active form of c-Src (Y527F) and harvested at 12 or 24 h post-transfection, respectively. We found an increased tyrosine phosphorylation upon transfection of constitutively active form of c-Src for 24 h (Figure 2). We have also observed that the Y416 in c-Src gets phosphorylated more in this state which points to the increased c-Src tyrosine kinase activity (Figure 2). In addition, the trend of increasing tyrosine phosphorylation could also serve as one more surrogate signature of substrates as one would expect the phosphorylation level to increase during this time course.

Mixing of light, medium and heavy isotope labeled cell lysates allowed us to compare the profile of proteins in a single MS experiment. In MS/MS spectra, fragmentation patterns generated by light, medium and heavy peptide pairs are identical except for the expected mass shift of the fragment ions. The ratio of the intensity of the heavier versus the light peptides provides information about the degree of phosphorylation of a protein and hence its enrichment upon expression of an active c-Src kinase. Thus, the greater the extent of phosphorylation of a protein by c-Src kinase, the higher should be its abundance in anti-phosphotyrosine antibody immunoprecipitates. Peptide sets with a little or no increase in intensity indicate that the protein is not different in abundance in the different states being compared. Such proteins were not investigated further as they are likely nonspecifically bound proteins. An increase in heavy/light intensity ratio, indicating an increase in total phosphotyrosine content upon Src kinase expression and activity, was found in peptides derived from 36 proteins (Tables 1 and 2). Of these, 10 proteins were either known Src family kinase substrates or proteins known to interact with Src family kinases (Table 1), whereas the remaining 26 proteins have not previously been described as substrates of c-Src or Src family members (Table 2) in higher eukaryotes. The known substrates identified in this screen included EWS1 (Ewing sarcoma breakpoint region 1),27 cortactin,28 calponin-3,29 hnRNPK (Heterogeneous nuclear ribonucleoprotein K),30,31 G3BP (GasGAP SH3-domain binding protein)32–34 and c-Src itself.35 The protein with maximum increase in tyrosine phosphorylation upon c-Src overexpression was c-Src itself. Other known and novel Src family substrates displayed >2-fold increase in intensity of phosphorylation. Apart from signaling and cytoskeletal proteins, we also identified DNA and RNA binding proteins in our analysis. Some of the reasons it is not possible in a kinase–substrate identification screen of this type to possibly identify every known substrate are (i) previously described substrates might not be expressed in the cell line that we have used; (ii) although the substrates might be expressed, they might not be abundant enough to be enriched and detected in our experiments; (iii) the phosphorylation might not occur or occur at a lower level in the cell that we have used; and (iv) the time course and kinetics of phosphorylation in the system that we have employed might be different from the systems previously used in the literature to describe substrates. Thus, although it is not possible to identify all of the known substrates of Src, identification of 6 known substrates of Src along with validation of some novel ones is indicative of the success of this type of phosphoproteomic screen.

We performed relative quantitation of tyrosine phosphorylation for each protein as a measure of increase in intensity ratios from light isotope to heavier isotope containing peptides (Supplementary Table 1). Figure 3 shows representative MS spectra for six of the proteins identified from our screen. In addition to identification of proteins with increased phosphorylation and quantitation, we also mapped 6 phosphorylation sites; Y334 in cortactin10 (Figure 4A) and Y72 in hnRNP-K30.
Figure 4B identified in this study were reported earlier. We also identified 4 novel tyrosine phosphorylation sites on each of EWS1 (Figure 4C), FUSE-binding protein 1 (Figure 4D), calponin-3 (Figure 4E) and FIP1-like1 (Figure 4F). We note that, although EWS1 was a known c-Src substrate, no tyrosine phosphorylation sites were previously localized.

One of the drawbacks of our experiments is that lysine was not available as 3 different isotopic forms at the time we initiated our experiments. By using 3 isotopes of lysine along with arginine, we would have obtained a better peptide coverage for each protein and likely identified additional proteins as substrates of c-Src. Nevertheless, we performed a lysine and arginine labeled SILAC experiment in a similar manner but followed by enrichment of phosphopeptides using antibodies against phosphotyrosine to see if we could identify phosphorylated peptides, but unfortunately, we could only identify 8 tyrosine phosphorylation sites (data not shown). We do not know the reasons for such a low yield. However, a protein IP serves our purpose of identifying the proteins that are substrates of Src even though the site is still not identified. This is the reason we coupled our approach with peptide microarrays to aid in identification of phosphopeptides.

Validation of a Subset of Novel c-Src Substrates. Further validation of the proteins identified by SILAC to prove that they are bona fide substrates usually involves the use of antibodies against these proteins. The validation of all of the protein candidates is not always possible, especially for novel proteins, as it depends on the availability of good antibodies. As commercial antibodies were not available for many of the proteins identified, we chose to investigate a subset of proteins, if they were direct substrates of c-Src using in vitro kinase assays. We selected NICE-4, RBM10, FBP1 and TRK-fused gene for this purpose, as their cDNAs were readily available. We used rabbit reticulocytes to perform in vitro transcription and
Identification of c-Src Kinase Substrates

Involvement of a Subset of Novel Substrates in Platelet-Derived Growth Factor Signaling. Since kinase activity of c-Src is required for modulating cellular responses to PDGF receptor stimulation, we chose to study the role of a subset of novel substrates in PDGF signaling. The role of c-Src has been well-studied in PDGF signaling. We investigated the involvement of EWS1, BTF and RBM10 in PDGF receptor signaling. Cortactin and p130CAS were used as positive controls. For this experiment, NIH3T3 cells, which express endogenous PDGF receptors, were treated with PDGF-BB in the presence or absence of a c-Src kinase inhibitor, SU6656 (2-oxo-3-(4,5,6,7-tetrahydro-1 H-indol-2-ylmethylene)-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamidine). By activating PDGF signaling in NIH3T3 cells, we investigated the ability of these proteins to get tyrosine-phosphorylated upon ligand-induced stimulation of the PDGF receptor. We found that all of the novel proteins were tyrosine-phosphorylated on stimulation of PDGF receptor (Figure 5C), as was the case with the two known substrates. Using SU6656, a potent inhibitor of c-Src kinase, we have shown the involvement of three novel proteins RBM10, EWS1 and BTF as c-Src substrates in PDGF signaling (Figure 5C). c-Src has been shown to have been involved in the regulation of nuclear proteins and transcription factors downstream of PDGF signaling and plays an important role in controlling DNA synthesis. We have also examined the involvement of RasGAP SH3-domain binding protein and thyroid hormone receptor associated protein 3 in PDGF signaling using SU6656 but could not detect any tyrosine phosphorylation of these proteins in any state (data not shown). Further experiments need to be done in order to examine the precise role of these proteins and the importance of their phosphorylation in PDGF signaling. One important caveat of these experiments using SU6656 for inhibition of Src kinase is that it could bind and inhibit other related kinases. When better inhibitors become available, this would be a great approach to identify the kinase–substrate relationships.

Ewing sarcoma breakpoint region 1 (EWS1) is an RNA binding protein and has been shown to be involved in gene translocations and often appear as fusion of EWS with ETS family transcription factor genes and known to cause Ewing sarcoma tumors. One of the fusion proteins EWS-Fli1 has been implicated in insulin-like growth factor 1 (IGF-1) as well as PDGF-BB induced proliferation of Ewing sarcoma cells. The implication of EWS1 as a downstream substrate of c-Src in PDGF-signaling might shed light into the mechanism of induction of proliferation by these genes in signaling and tumors. Bcl-2-associated transcription factor 1 (BTF) is an

Table 2. List of Novel Potential Src Substrates Identified Using SILAC by Overexpression of Src Kinase in 293T Cells

| accession no. | protein                                                   | fold increase (heavy/light) ± SD |
|--------------|-----------------------------------------------------------|---------------------------------|
| NP_005454    | Heterogeneous nuclear ribonucleoprotein D-like            | 10.0 ± 5.2                      |
| NP_113680    | RNA binding motif protein 4B                               | 9.4 ± 3.7                       |
| NP_003760    | Splicing factor, arginine/serine-rich 9                   | 9.3 ± 3.6                       |
| NP_004490    | Heterogeneous nuclear ribonucleoprotein AB                | 8.0                             |
| NP_005667    | RNA binding motif protein 10                               | 7.2 ± 0.6                       |
| NP_003803    | FUSE binding protein                                       | 6.9 ± 0.8                       |
| NP_055662    | NICE-4                                                    | 6.6 ± 2.1                       |
| NP_919223    | Heterogeneous nuclear ribonucleoprotein A3                | 6.1 ± 2.5                       |
| NP_003676    | FUSE binding protein                                       | 5.7 ± 2.2                       |
| NP_004951    | FUS/TLS oncogene                                          | 5.0 ± 0.9                       |
| NP_005649    | A-kinase anchor protein 8                                  | 5.5                             |
| NP_055554    | Bcl-2-associated transcription factor 1                    | 5.5                             |
| NP_877952    | Arsenate resistance protein ARS2                           | 5.4                             |
| NP_47335    | FUS interacting protein (serine/arginine-rich) 1            | 5.1                             |
| NP_005150    | Thyroid hormone receptor associated protein 3              | 5.1                             |
| NP_008937    | Cleavage and polyadenylation specific factor 5             | 4.8 ± 3.1                       |
| XP_028253    | Similar to Zinc finger CCCH-type domain-containing protein 6 | 3.8 ± 1.9                      |
| NP_079222    | NEFA-interacting nuclear protein                            | 3.8 ± 0.8                       |
| NP_060082    | Zinc finger, CCHC domain containing 8                      | 3.7                             |
| NP_005057    | Splicing factor proline/glutamine-rich                     | 3.1 ± 1.0                       |
| NP_005780    | Proteasome activator subunit 3                             | 2.6 ± 0.4                       |
| NP_006061    | TRK-fused gene                                             | 2.4                             |
| NP_003746    | Eukaryotic translation initiation factor 3, subunit 4       | 2.2                             |
| NP_663760    | Ataxin 2 related protein                                    | 2.2                             |
| NP_067038    | Chromosome 20 open reading frame 77                       | 2.0 ± 0.3                       |
| NP_057123    | Homeobox prox 1                                            | 2.0 ± 0.3                       |

*a* Heavy refers to Arg '10' and light refers to Arg '0' containing peptides.
apoptotic transcriptional repressor localized to the nucleus, whose function is still under investigation. RNA binding motif 10 (RBM10) is an RNA binding protein with a zinc finger domain, associated with the expression of Bax family members in breast cancers and VEGF. This was the first time BTF and RBM10 were identified as a tyrosine-phosphorylated proteins and the finding that they are components of PDGF signaling downstream of c-Src might help to understand the role of BTF and RBM10 in growth factor receptor signaling. Although we have observed tyrosine phosphorylation of a subset of proteins in PDGF signaling, it is not possible to validate all candidates in any proteomics experiment because of the following reasons: (i) Availability of good immunoprecipitating antibodies against these proteins is limited, and hence, we have tagged a subset of these proteins to show that these are indeed substrates; and (ii) To validate these proteins in a specific signaling pathway, it is not easy to predict in which signaling pathway(s) these proteins are involved downstream of c-Src. However, studies are currently in progress on a subset of proteins to show their physiological relevance and also to identify tyrosine-phosphorylated proteins in growth factor signaling pathways downstream of Src kinase.

**Development of Peptide Microarrays for High-Throughput Validation of c-Src Substrates.** Although we have established above that a number of novel proteins are potential substrates of c-Src, the exact residues that undergo phosphorylation have not been identified in most of these instances. Hence, we developed a custom peptide microarray as a platform to rapidly

**Figure 3.** MS spectra of 6 proteins identified as Src substrates by SILAC. The 3 spectral peaks in each figure represent the mass shift of the same peptide. The relative increase in intensity ratios between light to heavy are represented below in parentheses. (A) A doubly charged peptide from cortactin (1:7); (B) a triply charged peptide from NICE-4 (1:7); (C) a doubly charged peptide from Bcl2-associated transcription factor (1:7.5); (D) a doubly charged peptide from FUSE-binding protein 1 (1:8); (E) a doubly charged peptide from FUSE-binding protein 2 (1:4); (F) a doubly charged peptide from RNA binding motif 10 (1:7.5).
identify the phosphopeptides on these proteins which are phosphorylated by c-Src. We systematically designed 312 peptides encompassing all tyrosines from 14 selected proteins (Table 3). These were synthesized in such a fashion that they contained the tyrosine residue being tested in the center. In parallel, an equal number of peptides that have the centric tyrosine residues mutated to phenylalanine were designed. In all, 624 WT or mutant (312 WT and 312 MUT) peptides from 14 proteins were spotted with each sequence being represented in triplicate, on to the glass slides as described earlier.\textsuperscript{18} The design of these peptide microarrays is analogous to DNA microarrays manufactured by Affymetrix for mRNA expression studies. c-Src kinase assays were performed on the peptide microarrays and the arrays subsequently exposed to phosphorimage screen.

Figure 4. MS/MS spectra of novel phosphorylation sites identified in this study. (A) Phosphopeptide NASTFEDVTQVSSApYQK derived from Cortactin; (B) phosphopeptide TDPYNASVSPDSSGPER derived from hnRNPK; (C) phosphopeptide QDHPSMGVpYGQESGG-FSGPGENR derived from Ewing sarcoma breakpoint region 1; (D) phosphopeptide IGGGATSLNSpYGYGGQK derived from FUSE-binding protein 1; (E) phosphopeptide GPSpYGLSAEVK derived from Calponin-3; (F) phosphopeptide TGAPQpYGSYTAPVNLNIK derived from FIP1-like 1.

In all, 624 WT or mutant (312 WT and 312 MUT) peptides from 14 proteins were spotted with each sequence being represented in triplicate, on to the glass slides as described earlier.\textsuperscript{18} The design of these peptide microarrays is analogous to DNA microarrays manufactured by Affymetrix for mRNA expression studies. c-Src kinase assays were performed on the peptide microarrays and the arrays subsequently exposed to phosphorimage screen.
Table 3. Peptides from the Newly Identified Src Substrates That Were Phosphorylated by c-Src on Peptide Microarrays

| accession no. | protein                  | phosphopeptide      |
|---------------|--------------------------|---------------------|
| NP_003893     | FUSE binding protein 1    | EVRNEYSRSSR         |
| NP_003876     | FUSE binding protein 2    | RQQAAAYADTS         |
| NP_005554     | BCL2-associated transcription factor 1 | EETEDYRQFRR     |
| NP_005667     | RNA binding motif protein 10 | ARGSSYGGTTST      |
| NP_006061     | TRK-fused Gene           | EPPVDSSSYQQQ        |
| NP_005745     | RasGAP SH3-domain-binding protein | NEDIDYDELVL       |
| NP_0063760    | A-Kinase related protein 8 | GQQGYKVRAGKG       |
| NP_005849     | A-kinase related protein 8 | RPSYSDYEFD         |
| NP_005110     | Thyroid hormone receptor associated protein 3 | NHRPYQNDRF       |
| NP_005792      | Adenylate cyclase 1      | OGYNGYSRQRQ        |
| NP_006833     | Splicing factor 3B subunit 2 | HMYQQQQQQ          |
| NP_005983      | Splicing factor LOC23211 | RYREYSPYPA         |

were not phosphorylated, and that the variation of WT-MUT intensities for those points was representative of nonphosphorylated peptides (Figure 6C). On the basis of the calculated FPRs, a line was drawn which separates the true positives from the remainder of the peptides.

From this analysis, we have identified phosphorylation sites on 12 out of 14 proteins that were spotted on peptide microarrays. Peptides containing multiple tyrosines were mutated systematically and all the tyrosine containing peptides were looked at along with their corresponding mutated counterparts to deduce the correct phosphorylated peptide. A total of 34 peptides from 12 proteins (Table 3) out of 312 peptides from 14 proteins spotted (Supplementary Table 2) were phosphorylated by c-Src in our analysis. This included 6 phosphopeptides from Bcl2-associated transcription factor 5 from Thyroid hormone receptor associated protein 3, and 4 phosphopeptides from ARS2. We did not detect phosphorylation on any of the peptides derived from two proteins, Zinc finger, CCHC domain containing 8 and Splicing factor 3B subunit 2. Splicing factor proteins were not phosphorylated, and that the variation of WT-MUT intensities for those points was representative of nonphosphorylated peptides (Figure 6C). On the basis of the calculated FPRs, a line was drawn which separates the true positives from the remainder of the peptides.

From this analysis, we have identified phosphorylation sites on 12 out of 14 proteins that were spotted on peptide microarrays. Peptides containing multiple tyrosines were mutated systematically and all the tyrosine containing peptides were looked at along with their corresponding mutated counterparts to deduce the correct phosphorylated peptide. A total of 34 peptides from 12 proteins (Table 3) out of 312 peptides from 14 proteins spotted (Supplementary Table 2) were phosphorylated by c-Src in our analysis. This included 6 phosphopeptides from Bcl2-associated transcription factor 5 from Thyroid hormone receptor associated protein 3, and 4 phosphopeptides from ARS2. We did not detect phosphorylation on any of the peptides derived from two proteins, Zinc finger, CCHC domain containing 8 and Splicing factor prolinc/glutamine-rich. Thus, peptide arrays allowed assignment of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput fashion and also served as an additional validation step for potential substrates of phosphorylation sites in a high-throughput function.
Identification of c-Src Kinase Substrates

Figure 6. (A) Peptide microarrays: in vitro kinase assays performed on peptide microarrays, where all tyrosine containing peptides and their corresponding Y → F mutant counterparts were spotted on glass slides. A representative section of the peptide microarray is magnified to show the signal corresponding to a peptide and its Y → F mutant. (B) A classical MvA plot displaying data pertaining phosphorylation intensities on peptide microarrays. The horizontal dotted lines indicate 2-fold difference of (log 2 WT + log 2 MUT/2). (C) A plot displaying classical and local false positive rates (FPR). The red line represents local false positive rate curve and the blue line represents the classical false positive rate. The vertical dotted line shows where the local FPR = 0.15. All peptides to the right of the vertical dotted line and above 2-fold (horizontal line) were selected as true positives.

approaches. Use of SILAC methodology allowed us to identify a number of known and novel substrates of c-Src in human embryonic kidney 293T cells. We identified 4 new phosphorylation sites and also validated a subset of the novel substrates as direct c-Src substrates using in vitro kinase assays. We corroborated our results for four proteins as direct substrates of c-Src. We also implicated three of the novel c-Src substrates as tyrosine-phosphorylated proteins in PDGF receptor signaling. Since identification of phosphopeptides is still a challenge in proteomics, we designed a custom peptide microarray platform for high-throughput identification of peptides phosphorylated by specific kinase, c-Src, in this case.

Using peptide microarrays, we identified 34 phosphopeptides phosphorylated by c-Src that are derived from 12 novel candidate substrate proteins that were identified by SILAC as potential c-Src substrates. Identification of the phosphopeptides from these 12 new substrates also provides validation of this approach. It is worth noting here that most tyrosine containing peptides were not phosphorylated by c-Src. Peptide microarray technology has its own limitations. Although it can help identify bona fide substrate peptides in many instances, it is possible that some sequences that are phosphorylated in vivo do not get phosphorylated because of lack of secondary and tertiary structure of the immobilized peptides. Further, although the peptide microarray analysis has shed light on the phosphopeptides preferentially phosphorylated by c-Src, these sites still remain to be investigated in vivo using other methodologies.

The present study offers many encouraging leads, such as the identification of tyrosine phosphorylation of a subset of new c-Src substrates that are components in the PDGF signaling downstream of c-Src. Clearly, further characterization of these novel sites and proteins will result in a significant expansion of our knowledge of the c-Src kinase signaling network. The significance of tyrosine phosphorylation on each of the newly discovered sites remains to be determined. In any case, these results demonstrate that c-Src-mediated tyrosine phosphorylation is extensive and implicates a number of hitherto unrecognized proteins as c-Src kinase substrates.

Acknowledgment. A.P. is supported by grants from the National Institutes of Health (CA106424 and U54 RR020839), Department of Defense Era of Hope Scholar award (WB1XWH-06-1-0428) and by the Beckman Young Investigator award. L.C. is supported by grants from the National Cancer Institute (P30 CA06973-44). We thank members of Pandey lab for fruitful discussions. We also thank Hopkins Expressionists Working Group for advice and comments on peptide microarray analysis. Jos Joore is VP of Array Technology at PepScan Systems. We also thank Jurriaan Tuynman and Maikel Peppelenbosch, Academic Medical Center, Amsterdam, The Netherlands, for their helpful suggestions on peptide microarrays.

Supporting Information Available: This material is available free of charge via the Internet at http://pubs.acs.org.

References

(1) Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13, 513–609.
(2) Olsen, J. V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.; Mortensen, P.; Mann, M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127, 635–648.
(3) Ficarro, S. B.; McCleland, M. L.; Stukenberg, P. T.; Burke, D. J.; Ross, M. M.; Shabanowitz, J.; Hunt, D. F.; White, F. M. Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat. Biotechnol. 2002, 20, 361–365.
(4) Beausoleil, S. A.; Villen, J.; Gerber, S. A.; Rush, J.; Gygi, S. P. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol. 2006, 24, 1285–1292.
(5) Molina, H.; Horn, D. M.; Tang, N.; Mathivanan, S.; Pandey, A. Global proteomic profiling of phosphoproteins using electron transfer dissociation tandem mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 2199–2204.
(6) Shah, K.; Shokat, K. M. A chemical genetic screen for direct v-Src substrates reveals ordered assembly of a retrograde signaling pathway. Chem. Biol. 2002, 9, 35–47.
(7) Lock, P.; Abram, C. L.; Gibson, T.; Courtois, S. A. A new method for isolating tyrosine kinase substrates used to identify fish, an SH3 and PX domain-containing protein, and Src substrate. EMBO J. 1998, 17, 4346–4357.
(8) Qiao, Y.; Molina, H.; Pandey, A.; Zhang, J.; Cole, P. A. Chemical rescue of a mutant enzyme in living cells. Science 2006, 311, 1293–1297.
Ibarrola, N.; Molina, H.; Iwahori, A.; Pandey, A. A novel proteomic screen for peptide interactions. J. Proteome Res. 2005, 4, 1661–1671.

Ibarrola, N.; Molina, H.; Iwahori, A.; Pandey, A. A novel proteomics approach for specific identification of tyrosine kinase substrates using [32P]tyrosine. J. Biol. Chem. 2004, 279, 15805–15813.

Krackmayer, J.; Blagoev, B.; Haack-Sorensen, M.; Kassem, M.; Mann, M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005, 308, 1472–1477.

Pandey, A.; Podtelejnikov, A. V.; Blagoev, B.; Bustelo, X. R.; Mann, M. Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 179–184.

Rush, J.; Moritz, A.; Lee, K. A.; Guo, A.; Goss, V. L.; Spek, E. J.; Zhang, J.; Schulze, W. X.; Mann, M. A novel proteomic screen for peptide–protein interactions. J. Biol. Chem. 2004, 279, 10756–10764.

Molina, H.; Parmigiani, G.; Pandey, A. Assessing reproducibility of a protein dynamics study using in vivo labeling and liquid chromatography tandem mass spectrometry. Anal. Chem. 2005, 77, 2739–2744.

Bomsztyk, K.; Superti-Furga, G.; Hentze, M. W. c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol. Cell. Biol. 2002, 22, 4535–4543.

Yang, J. P.; Reddy, T. R.; Truong, K. T.; Subasini, M.; Wong-Staal, F. Functional interaction of Sam68 and heterogeneous nuclear ribonucleoprotein K. Oncogene 2002, 21, 7187–7194.

Rahmoni, S.; Vang, T.; Alonso, A.; Williams, S.; van Stipdonk, M.; Soncini, C.; Moutschen, M.; Schoenberger, S. P.; Mustelin, T. Removal of C-terminal SRC kinase from the immune synapse by a new binding protein. Mol. Cell. Biol. 2005, 25, 2227–2241.

Parker, F.; Maurier, F.; Delueme, I.; Duchesne, M.; Fauchier, D.; Debussche, L.; Dugue, A.; Schweighoffer, F.; Tocque, B. A Ras-GTPase-activating protein SH3-domain binding protein. Mol. Cell. Biol. 1996, 16, 2561–2569.

Cichowski, K.; McCormick, F.; Brugge, J. S. p21rasGAP association with Fyn, Lyn, and Yes in thrombin-activated platelets. J. Biol. Chem. 1992, 267, 5025–5031.

Ninghui, K.; Sheng, J. Activation and suppression of pp60c-src transforming activity by mutation of its primary sites of tyrosine phosphorylation. Cell 1987, 49, 65–73.

Ohan, N.; Sabourin, D.; Booth, R. A.; Liu, X. J. Xenopus laevis TRK- fused gene (TFG) is an SH3 domain binding protein highly expressed in the cement gland. Mol. Reprod. Dev. 2000, 56, 336–344.

Broome, M. A.; Hunter, T. Requirement for c-src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling. J. Biol. Chem. 1996, 271, 16798–16806.

Blake, R. A.; Broome, M. A.; Liu, X.; Wu, J.; Gishikzy, M.; Sun, L.; Courtneidge, S. A. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell. Biol. 2000, 20, 9018–9027.

Shah, K.; Vincent, F. Divergent roles of c-Src in controlling platelet-derived growth factor-dependent signaling in fibroblasts. Mol. Biol. Cell 2005, 16, 5418–5432.

Delatte, O.; Zucman, J.; Plougastel, B.; Desmaze, C.; Melot, T.; Peter, M.; Kovar, H.; Joubert, I.; de Jong, P.; Rouleau, G.; et al. Gene fusion with an ETS DNA-binding domain in the t(12;16) translocation in human tumours. Nature 1992, 359, 162–165.

Prieur, A.; Tirode, F.; Cohen, P.; Delatte, O. EWS-F11 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 2004, 24, 7275–7283.

Naszwa, S.; Ohto, H.; Banno, Y.; Doijima, T.; Wakahara, K.; Fan, D. G.; Shimizu, K. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-F11 via down-regulation of phospholipase D2 in Ewing sarcoma cells. J. Biol. Chem. 2005, 280, 27544–27551.

Kasof, G. M.; Goyal, L.; White, E. Bf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol. Cell. Biol. 1999, 19, 4390–4404.

Martinez-Aribas, F.; Agudo, D.; Pollan, M.; Gomez-Esquerr, F.; Daz-Gil, G.; Lucas, R.; Schneider, J. Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer. J. Cell. Biochem. 2006, 97, 1275–1282.

Bernard, O. C.; Cunningham, A. L.; Sheil, M. M. Analysis of proteins copurifying with the CD4/leuk cell complex using one-dimensional polyacrylamide gel electrophoresis and mass spectrometry: comparison with affinity-tag based protein detection and evaluation of different solubilization methods. J. Am. Soc. Mass Spectrom. 2004, 15, 558–567.

Scott, M. P.; Zapparoli, F.; Kim, E. Y.; Annan, R. S.; Miller, W. T. Identification of novel SH3 domain ligands for the Src family kinase Hck. Wiskott-Aldrich syndrome protein (WASP), WASP-interacting protein (WIP), and ELMO1. J. Biol. Chem. 2002, 277, 28238–28246.

PR800198W